Can­del’s promis­ing Ph2 da­ta in pan­cre­at­ic can­cer; Mi­cro­bio­me biotech rais­es £27M

Plus, news about Man­i­fold and Phe­nomix:

Can­del Ther­a­peu­tics’ vi­ral im­munother­a­py im­press­es in pan­cre­at­ic can­cer: In a small Phase 2 tri­al for pa­tients with bor­der­line re­sectable …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER